ArticleQuantitative imaging in medicine and surgery2026
Early postoperative recurrence prediction in pancreatic ductal adenocarcinoma: a nomogram based on dual-energy computed tomography and
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Given the poor prognosis of patients with pancreatic ductal adenocarcinoma (PDAC), the accurate stratification of patients at high risk for early recurrence (ER) is an urgent need. Conventional predictors such as carbohydrate antigen 19-9 (CA19-9) and tumor diameter have suboptimal efficacy. Quantitative parameters derived from dual-energy computed tomography (DECT) and the Methods: In this single-center retrospective study, we analyzed 80 patients diagnosed with pathologically confirmed PDAC from November 2021 to July 2023. ER was defined as disease relapse within 12 months postoperatively, and patients were categorized into ER and non-early recurrence (non-ER) groups. Clinicopathological variables, including tumor markers, pathological T stage (pTs), pathological N stage (pNs), tumor location, maximum tumor diameter, perineural invasion (PNI), and lymphovascular invasion (LVI), were collected. The following preoperative DECT parameters were obtained: dual-energy index (DEI), effective atomic number (Zeff), electron density (Rho), fat fraction, iodine concentration (IC), normalized iodine concentration (NIC), and vascular involvement. The maximum standardized uptake value (SUV Results: Comparative analysis revealed significant differences between the non-ER and ER groups in terms of the maximum tumor diameter, serum CA19-9 level, pNs, LVI, portal-venous-phase (PV-NIC) value, number of veins involved, and SUV Conclusions: The nomogram model based on DECT parameters, the PET/CT SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.